March 15, 2010

Bladder

A Phase II Multi-center, Non-Randomized, Open-label Study of TKI258 in Patients with Either FGFR3 Mutated or FGFR3 Wild Type Advanced Urothelial Carcinoma

Breast
Neo-Adjuvant

Neoadjuvant Weekly nab-paclitaxel (Abraxane) Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide with Bevacizumab Added Concurrently To Chemotherapy for Palpable and Operable Triple Negative Invasive Breast Cancer

Breast
Adjuvant

A Randomized, Multi-Center, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer

A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab

Breast
Metastatic

1st Line
Phase II Trial of Capecitabine in Combination with Fulvestrant for Postmenopausal Women with Hormone Receptor Positive Metastatic Breast Cancer

A Randomized, Open-label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women with HER2/neu Positive Metastatic Breast Cancer

1st or 2nd Line
A Phase II, Single-Arm, Multi-Center Study Evaluating the Combination of Vinorelbine and Lapatinib in Women with ErbB2 Overexpressing Metastatic Breast Cancer

2nd Line
A Double-Blind, Randomized Phase 2b Study of Sorafenib Compared when Administered in Combination with Chemotherapy for Patients with Locally advanced or Metastatic Breast Cancer that has Progressed During or After Bevacizumab Therapy

2nd Line or >
An Open-Label, Phase 1b Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination with other Anti-Cancer Treatment in Patients with Solid Tumors- Cross over into Phase 2

2nd Line or >
A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of IPI-504 in Combination with Trastuzumab in Patients with Pretreated, Locally Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)- Positive Breast Cancer.

2nd or 3rd Line
Phase I/II Trial of Dasatinib plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer

Colo-Rectal

1st Line
A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination with mFOLFOX6 to the Efficacy of Bevacizumab in Combination with mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer

A Phase I Trial Evaluating mFOLFOX6 and Avastin with Nexavar as First-Line Treatment for Metastatic Colorectal Cancer

1st or 2nd Line
An Open-Label, Dose-Finding Study to evaluate the Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects with Metastatic Colo rectal Cancer

2nd or 3rd Line
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients with Metastatic Colorectal Carcinoma (mCRC)

Gastric

1st Line
A Phase 2, Open-label Study Evaluating the Efficacy and Safety of Telatinib in Combination with Chemotherapy as First-Line in Subjects with Advanced Gastric Cancer

Gynecological

1st or 2nd Line
Chemoresponse Assay Validation Trial

1st Line
Phase I Everolimus Dose Finding Study for the Treatment of Stage IV or Recurrent, Non-resectable, Cervical Cancer with Standard Whole Pelvic Radiation Therapy in Combination with Cisplatin and Daily Everolimus

2nd or 3rd Line
A Phase I Trial of Oral Metronomic Topotecan in Combination with Oral Pazopanib Utilizing a Daily Dosing Schedule to Treat Recurrent or Persistent Gynecologic Tumors

Leukemia

CLL
A Phase III, Open-Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects with Relapsed Chronic Lymphocytic Leukemia

CLL
Ofatumumab Maintenance Treatment versus No Further Treatment in Relapsed CLL Responding to Induction Therapy

CML
A Multi-Center, Open-label, Exploratory Study of Bcr-Abl Kinetics in Adult Patients on Nilotinib with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic phase (CML-CP) and a Suboptimal Molecular Response to Imatinib

Lung NSCLC
Adjuvant

A Double-blind, Randomized, Placebo-controlled Phase III Study to Assess the Efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-positvenon-small Cell Lung Cancer

Metastatic

1st Line
A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination with Platinum-Based Chemotherapy as First line Treatment of Patients with Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

Randomized, Open-label, Phase 3 Study of Pemetrexed plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer

A Phase 1b/2 Study of AMG 479 in Combination with Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Lung Small Cell

A Phase 2 Study of LY2523355 in Patients with Extensive Stage Small Cell Lung Cancer

Melanoma

2nd Line
A Phase 2 Study of LY573636 Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle as Second-Line Treatment in Patients with Unresectable or Metastatic Melanoma
Pancreatic

1st Line
A Randomized Dose Escalation, Safety and Exploratory Efficacy Study of Kanglaite Injection Plus Gemcitabine Versus Gemcitabine in Patients with Advanced Pancreatic Cancer
Prostate

1st Line
A Randomized Phase 2 Study of LY2181308 Sodium in Combination with Docetaxel Versus Docetaxel in Hormone Refractory Prostate Cancer

2nd Line
A Multicenter, Randomized, Double-blind, Phase 3 Study of Sunitinib Plus Prednisone Versus Prednisone in Patients with Progressive Metastatic Hormone-Refractory Prostate Cancer After Failure or a Docetaxel-Based Chemotherapy Regimen

Renal
Adjuvant

Sunitinib Treatment of Renal Adjuvant Cancers (S-TRAC): A Randomized Double-Blind Phase 3 Study of Adjuvant Sunitinib Vs. Placebo in Subjects at High Risk of Recurrent RCC

Metastatic

An Open-label, Multicenter Phase II Study to Compare the Efficacy and Safety of RAD001 as First-Line Followed by Second-line Sunitinib versus Sunitinib as First Line Followed by Second-line RAD001 in The Treatment of Patients with Metastatic Renal Cell Carcinoma